Opsumit® (macitentan) is an orally available endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target of developing an ERA to address efficacy and safety
Tracleer® (bosentan) is an oral dual endothelin receptor antagonist. Tracleer is the only oral PAH therapy with an established safety and tolerability profile in more than 80,000 patients worldwide.
Veletri® (Epoprostenol for Injection)
Veletri® (Epoprostenol for Injection) is intravenous prostacyclin. Unlike other epoprostenol formulations approved for PAH, Veletri® is stable at room temperature (77 F, 25 C) for up to 48 hours when administered immediately upon reconstitution and dilution, making the use of frozen gel packs unnecessary.
Ventavis® (inhaled iloprost) is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclin (PGI2) – a naturally occurring molecule that causes blood vessels to dilate, limits cellular hypertrophy, and inhibits platelet aggregation.